Novartis’ Kymriah first cell therapy to win US green light
Novartis’ Kymriah has become the first ever CAR-T cell therapy to win approval in the US, bringing paediatric and young adult patients with B-cell acute lymphoblastic leukaemia a novel treatment approach.
Read More
